Clinical Trial Update: Efficacy and Safety of Alflutinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer Patients With T790M [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating alflutinib in EGFR T790M-positive locally advanced or metastatic non-small cell lung cancer has been terminated. The update provides …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Alflutinib (alflutinib)

Snippet

Sponsor: Allist Pharmaceuticals, Inc. | Conditions: Advanced NSCLC Patients With T790M | Phase 2 | Status: TERMINATED